Even higher rates of third-generation cephalosporin resistance in E. coli (>65% in 6/6 WHO regions), conferred by extended spectrum beta-lactamase enzymes, means that treatment of multidrug resistant (MDR) E. coli infections must now rely on last-line drugs, such as carbapenems or colistins. This evidence concerns the gene LACTB and infection.